Peter MacCallum Cancer Centre | Department of Clinical Hematology

Research site

(Unclaimed)

Location

305 Grattan Street, Melbourne, Victoria, Australia

Site insights

Top conditions

Top treatments

Pembrolizumab

Atezolizumab

Tislelizumab

Lenalidomide

Palbociclib

Abemaciclib

Cisplatin

Encorafenib

Enzalutamide

Platinum

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

146 of 322 total trials

A Clinical Study of the Safety and Effectiveness of an Investigational Cell Therapy Given With and Without an Investigational RNA-based Vaccine in Patients With Organ Tumors

This is a Phase I, FIH, open-label, multicenter, dose escalation trial with expansion cohorts to evaluate safety and preliminary efficacy of claudin...

Enrolling

Solid Tumor

Biological: CLDN6 CAR-T

Biological: CLDN6 uRNA-LPX/CLDN6 modRNA-LPX

A Diagnostic Imaging Study of 64Cu-SARTATE Using PET on Patients With Known or Suspected Neuroendocrine Tumors (DISCO)

The purpose of this study is to assess the performance of imaging agent 64Cu-SARTATE in participants with known or suspected Gastroenteropancreatic (...

Active, not recruiting

Neuroendocrine Tumors

Drug: 64Cu-SARTATE

A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

This is a Phase I/II, multicenter, open-label, dose-escalation study designed to evaluate the efficacy, safety, tolerability and pharmacokinetics (PK...

Enrolling

Non-Hodgkin's Lymphoma

Drug: Glofitamab

Drug: Obinutuzumab

A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors (FLAGSHP-1)

* To evaluate the safety and tolerability of escalating doses of ERAS-601 when administered as a monotherapy and in combination with other cancer the...

Active, not recruiting

Advanced or Metastatic Solid Tumors

Drug: Pembrolizumab

Drug: ERAS-601

Locations recently updated

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

Study consists of two main parts to explore BGB-16673 recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation...

Enrolling

Waldenström Macroglobulinemia

Marginal Zone Lymphoma

Drug: BGB-16673

A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer (CAMPFIRE)

The main purpose of the master is to help the research sites and sponsor carry out several clinical trials more efficiently by providing a common res...

Enrolling

Child

Neoplasms

Drug: Docetaxel

Drug: Ramucirumab

A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL) (COALITION)

This is an open label, multi-centre, phase Ib/II, parallel arm study evaluating the safety and tolerability of glofitamab in addition to backbone che...

Active, not recruiting

High-grade B-cell Lymphoma

Diffuse Large B Cell Lymphoma

Drug: Rituximab

Drug: Polatuzumab vedotin

A Phase 1/2 Study of the Safety and Efficacy of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL

The main purpose of this study is to evaluate the safety, recommended dose, and preliminary anti-tumor activity of WU-CART-007 in patients with relap...

Active, not recruiting

T-cell Acute Lymphoblastic Leukemia

Lymphoblastic Lymphoma

Biological: WU-CART-007

A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

This study will evaluate the efficacy and safety of glofitamab in combination with gemcitabine plus oxaliplatin (Glofit-GemOx) compared with rituxima...

Enrolling

Diffuse Large B-cell Lymphoma

Drug: Oxaliplatin

Drug: Tocilizumab

A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity (SU2C-SARC032)

This is an open-label, multi-institutional phase II randomized study comparing neoadjuvant radiotherapy followed by surgical resection to neoadjuvant...

Active, not recruiting

Soft Tissue Sarcoma of the Extremity

Drug: Pembrolizumab

A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)

This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX110 in subjects with relapsed or refractory B-cell malig...

Active, not recruiting

Adult B Cell ALL

B-cell Lymphoma

Biological: CTX110

A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma

This is a single-arm, open-label, multicenter, Phase 1 study evaluating the safety and efficacy of CTX120 in subjects with relapsed or refractory mul...

Active, not recruiting

Multiple Myeloma

Biological: CTX120

A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma (CARTITUDE-4)

The purpose of this study is to compare the efficacy of JNJ-68284528 (ciltacabtagene autoleucel \[cilta-cel\]) with standard therapy, either Pomalido...

Active, not recruiting

Multiple Myeloma

Drug: Pomalidomide

Drug: Bortezomib

Locations recently updated

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

The primary objective of this study is to compare progression-free survival (PFS) in participants who receive sotorasib with platinum doublet chemoth...

Enrolling

Non-Small Cell Lung Cancer (NSCLC)

Drug: Sotorasib

Drug: Pembrolizumab

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with breast cancer. Cohort 1 will focus on participants wit...

Enrolling

Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer

Drug: Palbociclib

Drug: Inavolisib

A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

This open-label, exploratory study is designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or combina...

Active, not recruiting

Metastatic Colorectal Cancer

Drug: Inavolisib

Drug: FOLFIRI

A Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-30813

This is a First in Human (FIH) Phase 1, multicenter, open label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharm...

Active, not recruiting

Advanced Solid Tumors

Drug: Tislelizumab

Drug: BGB-30813

A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer (CYCLONE 2)

This study is being done to see how safe and effective abemaciclib is when given together with abiraterone acetate plus prednisone in participants wi...

Active, not recruiting

Prostate Cancer

Drug: Prednisone

Drug: Placebo

A Study of AK112, a PD-1/VEGF Bispecific Antibody, for Advanced Solid Tumors

This study is to characterize the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activity of AK112...

Enrolling

Neoplasms Malignant

Drug: AK112